Is lenvatinib effective for renal cell carcinoma?
['However, the combination of lenvatinib, a multitargeted agent that inhibits VEGF as well as FGF receptors, and everolimus demonstrated promising results in a randomized phase II trial. ', 'The FDA has approved the combination of lenvatinib and everolimus to treat advanced or metastatic renal cell carcinoma.', 'Moreover, a recent Phase II study demonstrated a significant benefit for the second-line combination treatment with everolimus plus lenvatinib (a novel TKI) in terms of progression-free survival and overall survival compared to the single-agent everolimus.', 'We then discuss two recently approved growth factor receptor antagonists i.e. cabozantinib and lenvatinib, and a recently approved checkpoint inhibitor, nivolumab, and issues pertaining to drug development, and future directions in treatment of metastatic RCC. ', 'INTERPRETATION: Lenvatinib plus everolimus and lenvatinib alone resulted in a progression-free survival benefit for patients with metastatic renal cell carcinoma who have progressed after one previous VEGF-targeted therapy. ', 'Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.', 'Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.']
['Yes, combination of lenvatinib and everolimus is approved to treat advanced or metastatic renal cell carcinoma.']
['yes']